The Broken Brown Egg and Progyny Announce the 2025 Awareness, Hope, and Activism Grant™ to Support BIPOC Individuals and Couples in Family Building
The AHA Grant is an extension of the Broken Brown Egg's mission to break down the unique barriers that Black individuals face when pursuing fertility and family building care. These challenges include financial obstacles, health disparities, and persistent social stigmas that often go unaddressed in traditional healthcare settings. By providing comprehensive support through education, specialized treatment access, financial assistance, and emotional resources, the grant creates pathways to parenthood that might otherwise remain out of reach.
'Every year I'm moved by the stories of resilience from our community members navigating fertility challenges,' said Regina Townsend, Founder, The Broken Brown Egg. 'This fourth year of the AHA Grant represents our growing impact and unwavering commitment to ensuring BIPOC individuals don't face these journeys alone. That true 'AHA moment' isn't just about awareness—it's about empowerment through opening the door to new possibilities on the path to parenthood.'
In addition to financial support for treatment, recipients of this year's grant will also receive enhanced medication support through Alto Pharmacy, a digitally powered pharmacy specializing in fertility care. Alto's comprehensive approach includes access to expert pharmacists seven days a week and flexible delivery options—including same-day courier service—ensuring medications arrive when and where patients need them most. Additionally, grant recipients will benefit from unlimited access to a dedicated Progyny Patient Care Advocate who will serve as their personal fertility coach, offering clinical education, guidance, and emotional support throughout their entire family building journey.
'At Progyny, we believe family building should be accessible to everyone,' said Janet Choi, MD, MSCP, Chief Medical Officer, Progyny. 'Through our continued partnership with The Broken Brown Egg, we're addressing the systemic inequities that have historically limited options for BIPOC individuals. When we combine evidence-based clinical resources with culturally competent support systems, we achieve outcomes that extend beyond individual treatments —we nurture hope and create lasting change for everyone.'
The grant application opens today, April 8, 2025, and welcomes submissions from U.S. citizens and legal residents aged 18-45. Applications will be accepted through May 12, with winners—selected by a distinguished panel of BIPOC infertility advocates and physicians—announced on May 19. For complete application instructions and eligibility requirements, visit The Broken Brown Egg's grant website at https://thebrokenbrownegg.org/aha-grant.
For more information on Progyny, visit www.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.
About The Broken Brown Egg
The Broken Brown Egg, Inc. exists to inform, empower, and advocate for individuals and couples experiencing infertility and reproductive health issues, with an emphasis on the Black experience of these concerns.
The Broken Brown Egg dismantles the stigmas associated with fertility in underserved populations through relatable and accessible programs and events. The organization provides resources and support for three major targets: Reproductive Justice and Health Equity, The Reproductive Health Careers Pipeline, and Empowerment & Community Building. Signature programming includes an online virtual support community, an annual Mother's Day wine sip for those experiencing infertility, and a robust empowerment network connecting researchers and journalists to participants of color.
The Broken Brown Egg, Inc. is a 501c3 tax-exempt organization headquartered in Chicago, Illinois. For more information, please visit www.thebrokenbrownegg.org.
Media:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Where Will Intuitive Surgical Be in 5 Years?
Key Points Sector rotation and a hot valuation are weighing on shares of Intuitive Surgical. The company still has a healthy growth runway ahead with its core da Vinci system. However, it's important to avoid overpaying for even the best of companies. 10 stocks we like better than Intuitive Surgical › Intuitive Surgical (NASDAQ: ISRG) is one of the best success stories you'll find in the healthcare sector. The company has helped patients worldwide as a pioneer in robotic-assisted surgery, and its business success has driven the stock to returns of over 25,000% since its initial public offering (IPO) in 2000. The company's flagship da Vinci system remains its crown jewel today and continues to drive profitable growth from an increasingly larger installed base. Yet the stock has wavered recently, currently sitting in the middle of its 52-week range. Is this a dip worth buying for the next five years, or is Intuitive Surgical losing its edge? Here is where the stock may go over the coming years. A hefty valuation could be weighing on the share price Intuitive Surgical currently trades at a price-to-earnings (P/E) ratio of 75. Meanwhile, analysts estimate the company will grow earnings by an average of just over 13.8% annually over the long term. The company has a sterling reputation for its long track record of business and investment performance; however, it's challenging to justify such a high valuation for the growth Wall Street anticipates. At the same time, the broader S&P 500 healthcare sector is trading near the low end of its 52-week range, which suggests that healthcare stocks aren't particularly popular at the moment. Although the broader stock market is near all-time highs, individual stocks, entire industries, or market sectors may be hot or cold at any given time. Sometimes, the simple explanation is the correct one. Market sentiment is working against the healthcare sector, so Intuitive Surgical's expensive valuation appears to be weighing on the stock. It happens. Intuitive Surgical still has more growth ahead That said, market dynamics can and will change over time, and five years is a considerable amount of time. Top-line and bottom-line growth tend to drive a stock's long-term performance, so it's essential to understand where a company stands in its business journey. Intuitive Surgical currently sells two systems: its da Vinci system, available in single- and multi-port configurations, used for a variety of soft tissue procedures, and the Ion, the company's newer system, used for performing minimally invasive peripheral lung biopsies. As of June 30, there are 10,488 da Vinci systems installed worldwide, generating recurring revenue for Intuitive Surgical as these systems consume supplies and require servicing over time. The global da Vinci installed base performed 17% more procedures in Q2 than the prior year, indicating that growth remains relatively healthy (no pun intended). The company estimates its core (da Vinci) addressable market at approximately 8 million annual soft tissue procedures, based on the da Vinci systems' current regulatory approvals and capabilities. Considering da Vinci systems will perform over 3 million procedures this year, it seems that Intuitive Surgical still has room for solid short- and medium-term growth, and that's speaking to organic growth, as in more installed systems and procedures. As a bonus, Intuitive Surgical has zero debt, is highly profitable, and has $4.5 billion in cash. Management could lean more into share repurchases to help grow its earnings per share. Given all of this, the 13% annualized growth rate Wall Street anticipates seems achievable. Where might the stock price be in five years? Investors can extrapolate this growth rate to see where the stock may trade over time. Applying that 13.8% growth rate to Intuitive Surgical's trailing-12-month earnings per share of $6.82, the company's earnings would grow something like this: 2026: $7.76 2027: $8.83 2028: $10.05 2029: $11.44 2030: $13.02 The stock has averaged a P/E ratio of 62 over the past 10 years, so here is where the stock may trade in five years, based on its current valuation and some other scenarios: Price-to-Earnings Ratio July 2030 Share Price Total Upside or Downside 75 $976 91% 65 $846 66% 55 $716 40% 45 $586 15% 35 $456 (11%) Calculations by author. If Intuitive Surgical reverts closer to its long-term averages, the current valuation could easily continue to weigh on the stock. Therefore, investors may want to err on the side of caution and focus on the lower valuations. If the broader market stumbles, Intuitive Surgical could even drop to a P/E ratio below its long-term norms. It's always good to build a margin of safety into these exercises. Intuitive Surgical hasn't lost its edge, but it is an overvalued stock. Investors may want to prepare for a five-year period in which the stock delivers underwhelming returns, in case Intuitive Surgical's valuation returns to a more appropriate level for its expected growth. Should you invest $1,000 in Intuitive Surgical right now? Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Intuitive Surgical wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool has a disclosure policy. Where Will Intuitive Surgical Be in 5 Years? was originally published by The Motley Fool
Yahoo
21 hours ago
- Yahoo
Wells Fargo Raises PT on Health Catalyst, Inc. (HCAT); Maintains ‘Buy' Rating
Health Catalyst, Inc. (NASDAQ:HCAT), having a share price under $10, strong hedge fund interest, and a low price-to-earnings ratio, ranks among the . A data center operator working on a rack of servers, emphasizing the company's cloud services. On July 1, 2025, Wells Fargo set its price target at $10 for Health Catalyst, Inc. (NASDAQ:HCAT), maintaining a 'Buy' rating. HCAT's shares are currently trading at around $4, implying a significant upside as per the analyst. The analyst believes that Health Catalyst, Inc. (NASDAQ:HCAT) is valued much lower than its peers, which sets the company up for future growth through consistent performance. The firm expects positive growth in the company's bookings in the upcoming Q2, which is likely to boost investor sentiment. Meanwhile, the company's strong revenue visibility for 2025 is noted, along with an anticipated acceleration in its DOS client growth. Looking ahead, the analyst expects the company to improve its dollar-based retention rate, enhancing its customer loyalty and revenue base. Legislative uncertainties, on the other hand, are expected to be short-term concerns with minimal long-term impact. Lastly, the company's EBITDA growth was also highlighted as a key reason for the optimistic outlook. With Health Catalyst Ignite, a cloud-based data and analytics platform, Health Catalyst, Inc. (NASDAQ:HCAT) serves healthcare entities, enhancing clinical, financial, and operational results. It is included in our list of the best cloud stocks. While we acknowledge the potential of HCAT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 14 Cheap Transportation Stocks to Buy According to Analysts and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None.
Yahoo
a day ago
- Yahoo
Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 14, the company delivered positive clinical data from the Phase 3 PaTHway Trial, which affirmed that TransCon PTH (palopegteriparatide) offered benefits to adults with hypoparathyroidism. A close-up of a pharmacist in a gleaming white labcoat holding a vial of biopharmaceuticals. Hypoparathyroidism is an endocrine disorder characterized by a deficiency of parathyroid hormone, which regulates the balance of calcium and phosphate. Serious side effects from the illness can include cognitive decline, renal problems, and neuromuscular irritability. The new three-year data for the Phase 3 PaTHway Trial, presented at the ENDO 2025 conference, showed improvements in biochemical markers, kidney function, and quality of life. Kidney function was maintained through week 156, as the mean glomerular filtration rate (eGFR) increased by 8.76 mL/min/1.73 m². No new safety concerns emerged during the trial phase, as the treatment was well-tolerated. 'These responses, including normalization of skeletal dynamics with significant and clinically meaningful improvements in kidney function, demonstrate the long-term benefits of this treatment option for the vast majority of adults with hypoparathyroidism,' said Aimee Shu, Executive Vice President and Chief Medical Officer at Ascendis Pharma. Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops new therapies to address unmet medical needs using the innovative TransCon technology platform. It focuses on rare endocrine diseases and oncology, with the goal of creating best-in-class treatments. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
